MetaVia Inc.

MetaVia Inc. announced it has filed a prospectus supplement for an At The Market Offering Agreement, allowing it to sell up to $4,000,000 of its common stock. The company initially entered into this agreement with Ladenburg Thalmann & Co. Inc. on November 6, 2025, which will act as the sales agent for the offering.

MetaVia Inc. held its 2026 virtual annual meeting where stockholders approved several key proposals. These included a reverse stock split with a ratio between 1-for-5 and 1-for-22, and an increase of 200,000 shares to the 2022 Equity Incentive Plan. Additionally, two Class I directors were elected, and the appointment of BDO USA, P.C. as the independent auditor for 2026 was ratified.

MetaVia Inc. presented new late-breaking data at the ADA 2026 Scientific Sessions highlighting its obesity and metabolic disease portfolio. Phase 1 results for DA-1726, a dual GLP1R/GCGR agonist, showed up to a 9.1% mean body weight reduction at Day 54 in obese adults. Preclinical data also supported combination treatment potential for vanoglipel (DA-1241), a GPR119 agonist, demonstrating synergistic effects in MASH and type 2 diabetes models when combined with other agents.

MetaVia Inc. announced new Phase 1 data for DA-1726, a dual GLP1R/GCGR agonist, presented at EASL 2026. The 48 mg cohort demonstrated favorable safety and tolerability, achieving up to 9.1% mean body weight reduction at Day 54 without titration. Exploratory FibroScan assessments also indicated early liver-related improvements, supporting its potential in obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company is continuing Phase 1 titration studies to evaluate longer-term dosing strategies.

MetaVia Inc. announced that three late-breaking abstracts highlighting its cardiometabolic assets, DA-1726 and vanoglipel (DA-1241), have been accepted for poster presentations at the American Diabetes Association’s (ADA) 2026 Scientific Sessions. DA-1726 is a dual GLP-1/glucagon agonist for obesity, currently in a Phase 1 titration study with data expected in Q4 2026. Vanoglipel, a GPR119 agonist, showed broad therapeutic potential for liver and metabolic diseases. Two preclinical posters for vanoglipel explore combination therapies for metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes.

MetaVia Inc. reported a net loss of $3.82 million for the first quarter of 2026, with a loss per share of $(0.79). The company's cash and cash equivalents increased to $13.73 million as of March 31, 2026, largely due to $7.1 million in net proceeds from a public offering and $0.3 million from an at-the-market offering. Despite these capital raises, MetaVia issued a going concern warning, citing ongoing net losses and negative cash flows from operations, which raise substantial doubt about its ability to continue operations for the foreseeable future.

MetaVia Inc. reported its first quarter 2026 financial results, with a net loss of $3.8 million. The company highlighted significant clinical progress for its lead obesity candidate, DA-1726, with Phase 1 data demonstrating 9.1% weight loss and improved glucose control. MetaVia also announced the dosing of the first patient in the Phase 1 Part 3 titration study for DA-1726, with data anticipated in the fourth quarter of 2026. The company's cash and cash equivalents increased to $13.7 million, supported by a $9.3 million public offering in January, providing runway into Q4 2026.

MetaVia Inc. announced that a late-breaking abstract highlighting its novel dual GLP-1/glucagon agonist, DA-1726, for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The presentation will take place on May 27, 2026, in Barcelona, Spain. DA-1726 is currently undergoing a 16-week Phase 1 Part 3 titration study, with data anticipated in the fourth quarter of this year, aiming to optimize higher dose levels and tolerability.

MetaVia Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 8, 2026. Key proposals include the election of two Class I directors and the ratification of BDO USA, P.C. as the independent auditor. Stockholders will also vote on a significant proposal to effect a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-22, and to increase the aggregate number of shares available under the 2022 Equity Incentive Plan by 200,000 shares. The Board unanimously recommends voting "FOR" all proposals.

MetaVia Inc. announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin (OXM) analog designed to target both GLP-1 and glucagon receptors. This advancement signifies continued progress in the company's clinical development pipeline for a potentially significant metabolic therapeutic. Part 3 of the trial is structured with two 16-week titration cohorts, aiming to assess various dose-escalation strategies to safely reach higher target doses and enhance the drug's tolerability profile. This step is crucial for optimizing the therapeutic potential of DA-1726 as it moves through early-stage development.